Recent developments in cell-based immune therapy for neuroblastoma

Michael R. Verneris, John E. Wagner

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Neuroblastoma (NB) is a common and aggressive tumor of early childhood. To date, treatment with chemotherapy, surgery, and radiation therapy has resulted in suboptimal outcomes in those with advanced disease. Immune-based treatments hold promise for patients with recurrent or advanced NB. Here, recent preclinical studies and early stage (phase I) clinical trials using cellular therapeutic approaches for NB are reviewed, including studies of natural killer cells, γδ T cells, chimeric receptor expressing T cells, dendritic cells, and allogeneic hematopoietic cell transplant.

Original languageEnglish (US)
Pages (from-to)134-139
Number of pages6
JournalJournal of Neuroimmune Pharmacology
Issue number2
StatePublished - Jun 2007

Bibliographical note

Funding Information:
This work was supported in part by grants from the Children’s Cancer Research Fund and the Minnesota Medical Foundation. M.R.Verneris(*) . J. E. Wagner Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Mayo Mail Code 366, 420 Delaware Street, S.E., Minneapolis, MN 55455, USA e-mail: [email protected]


  • Allogeneic transplantation
  • Dendritic cells
  • Gd T cells
  • Immune therapy
  • Immunotherapy
  • NK cells
  • T cells
  • Vaccine


Dive into the research topics of 'Recent developments in cell-based immune therapy for neuroblastoma'. Together they form a unique fingerprint.

Cite this